Hantz Financial Services Inc. Buys New Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Hantz Financial Services Inc. purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,051 shares of the company’s stock, valued at approximately $3,435,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Riverview Trust Co bought a new position in shares of IDEXX Laboratories during the 1st quarter worth approximately $26,000. Crewe Advisors LLC acquired a new position in IDEXX Laboratories during the first quarter worth $26,000. Ridgewood Investments LLC bought a new position in shares of IDEXX Laboratories during the second quarter valued at $27,000. Institutional & Family Asset Management LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $28,000. Finally, DSM Capital Partners LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $33,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 1.2 %

NASDAQ IDXX opened at $481.33 on Friday. The stock has a market capitalization of $39.75 billion, a P/E ratio of 46.60, a price-to-earnings-growth ratio of 3.91 and a beta of 1.32. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. The stock has a fifty day moving average of $481.86 and a 200-day moving average of $507.82.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the business earned $2.67 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 6.4% compared to the same quarter last year. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. Morgan Stanley cut their target price on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research note on Tuesday, May 14th. Piper Sandler decreased their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Finally, BTIG Research initiated coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $582.25.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.